COMPANY PROFILE // THE 014 REPORT
Skye Bioscience, Inc.
SKYE (Nasdaq) · Formerly: Emerald Bioscience, Inc.; Nemus Bioscience, Inc.; LOAD GUARD LOGISTICS, INC.; LOAD GUARD TRANSPORTATION, INC.
Assembled from 2 government sources in 0.2 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber5 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-09-11: a pattern of leadership change.
- Amber8-K Item 3.01 filed: notice of delisting, of a failed continued-listing rule, or of a transfer of listing on 2026-08-19 and 2 more times (last 24 months).
- Amber8-K Item 4.01 filed: change in the company's certifying accountant (auditor) on 2025-06-11 (last 24 months).
✓ SEC filings✗ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
Skye Bioscience, Inc. is an SEC-registered operating company in pharmaceutical preparations, incorporated in NV, based in San Diego, CA; listed as SKYE (Nasdaq).[source] It has filed 65 documents with the SEC in the last 12 months; the latest is Form 10-Q, filed 2026-11-13.[source] Seraphix flags 3 items from these records: 8-K Item 4.01 filed; 8-K Item 3.01 filed; 5 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-09-11.[source]
- red0
- amber3
- info0
- CLEAR26
- POSSIBLE MATCH0
- MATCH0
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- ARSENAULT KAITLYN · Chief Financial Officer (Officer) · latest Form 4 2026-02-09 · filing · LinkedIn search
- Arora Puneet S. · Chief Medical Officer (Officer) · latest Form 4 2026-02-09 · filing · LinkedIn search
- DHILLON PUNIT · Chief Executive Officer (Director,Officer) · latest Form 4 2026-02-09 · filing · LinkedIn search
- Diep Tuan Tu · Chief Development Officer (Officer) · latest Form 4 2026-02-09 · filing · LinkedIn search
- Twitty Christopher · Chief Scientific Officer (Officer) · latest Form 4 2026-02-09 · filing · LinkedIn search
- Charych Deborah H. · Director · latest Form 4 2026-02-09 · filing · LinkedIn search
- Grayson Paul A. · Director · latest Form 4 2026-02-09 · filing · LinkedIn search
- Jenkins Annalisa · Director · latest Form 4 2026-02-09 · filing · LinkedIn search
- Schwab Andrew J. · Director · latest Form 4 2026-02-09 · filing · LinkedIn search
- Smith Karen L. · Director · latest Form 4 2026-02-09 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001516551 | source |
| EIN | 45-0692882 | source |
| Business address (SEC) | 11250 EL CAMINO REAL, SUITE 100, SAN DIEGO, CA, 92130 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 130 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 175 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Mereo BioPharma Group plc · Jenkins Annalisa
- COMPASS Pathways plc · Jenkins Annalisa
- Camp4 Therapeutics Corp · Schwab Andrew J.
- SANGAMO THERAPEUTICS, INC · Smith Karen L.
- Context Therapeutics Inc. · Smith Karen L.
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-13 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-12 filing DEFA14A · SEC EDGAR
- 2026-11-12 filing 8-K items 8.01 · SEC EDGAR
- 2026-10-28 filing PRER14A · SEC EDGAR
- 2026-10-26 filing PREM14A · SEC EDGAR
- 2026-09-24 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-09-11 filing DEFA14A · SEC EDGAR
- 2026-09-11 officer change 8-K items 1.02,5.02,8.01 · SEC EDGAR
- 2026-08-24 filing DEFA14A · SEC EDGAR
- 2026-08-24 filing 8-K items 1.01,3.02,9.01 · SEC EDGAR
- 2026-08-20 filing DEFA14A · SEC EDGAR
- 2026-08-20 filing 8-K/A items 3.03 · SEC EDGAR
- 2026-08-19 filing DEFA14A · SEC EDGAR
- 2026-08-19 filing 8-K items 3.01 · SEC EDGAR
- 2026-08-18 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-08-14 filing DEFA14A · SEC EDGAR
- 2026-08-14 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-14 officer change 8-K items 1.01,3.02,3.03,5.01,5.02,5.03,7.01,9.01 · SEC EDGAR
- 2026-06-23 filing 8-K items 8.01 · SEC EDGAR
- 2026-05-29 filing 8-K items 5.03,5.07,9.01 · SEC EDGAR
- 2026-05-15 filing 8-K items 3.01 · SEC EDGAR
- 2026-05-11 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-04-16 filing ARS · SEC EDGAR
- 2026-04-16 filing DEFA14A · SEC EDGAR
- 2026-04-16 filing Proxy statement · SEC EDGAR
- 2026-04-06 filing PRE 14A · SEC EDGAR
- 2026-04-06 filing PREM14A · SEC EDGAR
- 2026-04-06 officer change 8-K/A items 5.02 · SEC EDGAR
- 2026-04-03 officer change 8-K items 5.02,9.01 · SEC EDGAR
- 2026-04-02 filing 3/A · SEC EDGAR
170 earlier entries
- 2026-03-19 filing 8-K items 3.01
- 2026-03-11 filing S-8
- 2026-03-10 filing 8-K items 2.02
- 2026-03-10 filing Annual report (10-K)
- 2026-02-20 officer change 8-K items 5.02
- 2026-02-09 insider First Form 3/4/5 on record for ARSENAULT KAITLYN (Chief Financial Officer)
- 2026-02-09 insider First Form 3/4/5 on record for Arora Puneet S. (Chief Medical Officer)
- 2026-02-09 insider First Form 3/4/5 on record for DHILLON PUNIT (Chief Executive Officer)
- 2026-02-09 insider First Form 3/4/5 on record for Diep Tuan Tu (Chief Development Officer)
- 2026-02-09 insider First Form 3/4/5 on record for Charych Deborah H. (Director)
- 2026-02-09 insider First Form 3/4/5 on record for Grayson Paul A. (Director)
- 2026-02-09 insider First Form 3/4/5 on record for Jenkins Annalisa (Director)
- 2026-02-09 insider First Form 3/4/5 on record for Smith Karen L. (Director)
- 2026-02-02 filing 8-K items 7.01,8.01,9.01
- 2025-12-23 filing 8-K items 1.01
- 2025-12-16 filing SCHEDULE 13D/A
- 2025-11-10 filing 8-K items 2.02,9.01
- 2025-11-10 filing Quarterly report (10-Q)
- 2025-10-06 filing 8-K items 7.01,9.01
- 2025-08-22 insider First Form 3/4/5 on record for Schwab Andrew J. (Director)
- 2025-08-07 filing 8-K items 2.02,9.01
- 2025-08-07 filing Quarterly report (10-Q)
- 2025-06-11 filing 8-K items 4.01,5.07,9.01
- 2025-05-08 filing 8-K items 2.02,9.01
- 2025-05-08 filing Quarterly report (10-Q)
- 2025-04-25 filing ARS
- 2025-04-25 filing DEFA14A
- 2025-04-25 filing Proxy statement
- 2025-04-25 insider First Form 3/4/5 on record for Twitty Christopher (Chief Scientific Officer)
- 2025-03-20 filing S-8
- 2025-03-20 filing 8-K items 2.02,9.01
- 2025-03-20 filing Annual report (10-K)
- 2025-02-26 officer change 8-K items 5.02,9.01
- 2025-02-05 filing UPLOAD
- 2024-12-23 filing CORRESP
- 2024-12-19 filing SCHEDULE 13D/A
- 2024-12-16 filing UPLOAD
- 2024-11-15 filing 144
- 2024-11-15 filing 144
- 2024-11-15 filing 144
- 2024-11-15 filing 144
- 2024-11-07 filing S-8
- 2024-11-07 filing Quarterly report (10-Q)
- 2024-11-07 filing 8-K items 2.02,9.01
- 2024-10-29 officer change 8-K items 5.02,8.01,9.01
- 2024-10-24 officer change 8-K items 5.02,5.07,9.01
- 2024-09-23 filing Proxy statement
- 2024-09-13 filing PRE 14A
- 2024-09-04 officer change 8-K items 5.02,7.01,9.01
- 2024-08-12 filing S-8
- 2024-08-09 filing S-8
- 2024-08-09 filing Quarterly report (10-Q)
- 2024-07-03 officer change 8-K items 5.02,7.01,9.01
- 2024-06-10 filing 8-K items 8.01,9.01
- 2024-05-17 filing EFFECT
- 2024-05-17 filing EFFECT
- 2024-05-17 filing 424B3
- 2024-05-15 filing CORRESP
- 2024-05-15 filing CORRESP
- 2024-05-15 filing CORRESP
- 2024-05-15 filing CORRESP
- 2024-05-14 filing UPLOAD
- 2024-05-14 filing UPLOAD
- 2024-05-10 filing S-3
- 2024-05-10 filing S-3
- 2024-05-10 filing Quarterly report (10-Q)
- 2024-04-26 filing EFFECT
- 2024-04-24 filing POS AM
- 2024-04-10 filing EFFECT
- 2024-04-10 filing 424B3
- 2024-04-10 filing CERT
- 2024-04-10 filing 8-A12B
- 2024-04-09 filing CORRESP
- 2024-04-09 filing CORRESP
- 2024-04-09 filing CORRESP
- 2024-04-04 filing S-1/A
- 2024-04-03 filing 8-K items 7.01,9.01
- 2024-04-02 filing UPLOAD
- 2024-03-27 filing Registration (S-1)
- 2024-03-27 filing D
- 2024-03-22 filing Annual report (10-K)
- 2024-03-13 filing SC 13D/A
- 2024-03-13 filing 8-K items 1.01,3.02,9.01
- 2024-03-04 officer change 8-K items 5.02,8.01,9.01
- 2024-02-12 filing 8-K items 8.01,9.01
- 2024-02-12 filing D
- 2024-01-31 filing SC 13D/A
- 2024-01-29 filing 8-K items 1.01,3.02,7.01,8.01,9.01
- 2023-12-22 filing S-8
- 2023-12-05 filing 8-K items 1.01,1.02,9.01
- 2023-11-14 filing Quarterly report (10-Q)
- 2023-11-07 filing 8-K items 5.03,9.01
- 2023-10-17 filing DEF 14C
- 2023-10-03 officer change 8-K items 5.02,8.01,9.01
- 2023-10-03 filing PRE 14C
- 2023-09-07 filing 8-K items 3.03,5.03,7.01,9.01
- 2023-09-01 officer change 8-K/A items 5.02
- 2023-08-29 filing D
- 2023-08-28 filing SC 13D
- 2023-08-21 officer change 8-K items 1.01,2.01,2.03,3.02,5.02,7.01,9.01
- 2023-08-07 filing Quarterly report (10-Q)
- 2023-05-12 filing Quarterly report (10-Q)
- 2023-03-31 filing Annual report (10-K)
- 2023-03-27 officer change 8-K/A items 5.02,9.01
- 2023-03-20 filing SC 13D/A
- 2023-03-03 filing 3/A
- 2023-02-23 filing 8-K items 1.01,1.02,3.02,9.01
- 2023-02-16 officer change 8-K items 5.02,8.01,9.01
- 2023-02-15 filing 8-K items 1.01,2.01,8.01,9.01
- 2023-01-27 filing 8-K items 1.01,7.01,9.01
- 2023-01-06 officer change 8-K items 1.01,5.02,9.01
- 2022-12-19 filing 8-K items 1.01,9.01
- 2022-11-23 filing 8-K items 1.01,3.03,9.01
- 2022-11-15 filing 3/A
- 2022-11-14 filing Quarterly report (10-Q)
- 2022-10-19 filing 8-K items 1.01,2.03,9.01
- 2022-10-03 filing 8-K items 4.01,5.07,7.01,9.01
- 2022-09-01 filing DEFA14A
- 2022-08-31 filing DEFM14A
- 2022-08-15 filing Quarterly report (10-Q)
- 2022-08-15 filing PREM14A
- 2022-07-21 filing 8-K items 1.01,9.01
- 2022-06-17 officer change 8-K items 1.01,4.01,5.02,9.01
- 2022-05-23 officer change 8-K items 1.01,5.02,9.01
- 2022-05-12 officer change 8-K items 1.01,3.02,5.02,8.01,9.01
- 2022-05-06 filing Quarterly report (10-Q)
- 2022-03-28 filing Annual report (10-K)
- 2022-01-31 filing SC 13D/A
- 2021-12-20 officer change 8-K items 5.02,8.01,9.01
- 2021-11-10 filing 424B3
- 2021-11-10 filing Quarterly report (10-Q)
- 2021-10-15 filing 8-K items 1.01,8.01,9.01
- 2021-10-06 officer change 8-K items 5.02,8.01,9.01
- 2021-09-30 filing 8-K items 7.01,9.01
- 2021-09-28 filing 8-K items 1.01,8.01,9.01
- 2021-09-28 filing 424B5
- 2021-09-15 officer change 8-K items 5.02,8.01,9.01
- 2021-08-09 filing EFFECT
- 2021-08-06 filing 424B3
- 2021-08-06 filing Quarterly report (10-Q)
- 2021-08-05 filing CORRESP
- 2021-08-04 filing UPLOAD
- 2021-07-29 filing S-3
- 2021-07-26 officer change 8-K items 5.02,8.01,9.01
- 2021-07-22 filing 8-K items 1.01,3.02,9.01
- 2021-05-07 filing 424B3
- 2021-05-07 filing Quarterly report (10-Q)
- 2021-03-02 filing 424B3
- 2021-03-02 filing Annual report (10-K)
- 2021-02-03 filing 8-K items 5.07
- 2021-01-19 filing 8-K items 5.03,8.01,9.01
- 2021-01-07 name change Name changed from Emerald Bioscience, Inc.
- 2020-12-22 filing Proxy statement
- 2020-12-11 filing PRE 14A
- 2020-11-09 filing 424B3
- 2020-11-06 filing Quarterly report (10-Q)
- 2020-09-28 officer change 8-K items 5.02
- 2020-08-17 filing SC 13D/A
- 2020-08-13 filing 424B3
- 2020-08-13 filing Quarterly report (10-Q)
- 2020-08-13 filing S-8
- 2020-08-12 officer change 8-K items 5.02,8.01,9.01
- 2020-08-05 filing 8-K items 1.01,8.01,9.01
- 2020-08-03 filing 424B4
- 2020-07-31 filing EFFECT
- 2020-07-31 filing S-1MEF
- 2020-07-29 filing CORRESP
- 2020-07-28 filing S-1/A
- 2020-07-16 filing UPLOAD
- 2020-07-13 filing Registration (S-1)
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-13 (within 30 days) 10-Q filed
- 2026-11-12 (within 30 days) DEFA14A filed
- 2026-11-12 (within 30 days) 8-K filed: Item 8.01 other event
- 2026-10-28 (within 30 days) PRER14A filed
- 2026-10-26 (within 30 days) PREM14A filed
- 2026-09-11 (older) DEFA14A filed
- 2026-09-11 (older) 8-K filed: Item 1.02 agreement terminated; Item 5.02 officer or director change; Item 8.01 other event
- 2026-08-24 (older) DEFA14A filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-21; the colour is also written out in words.
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:SKYE The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
0 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1516551 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | SKYE / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 450692882 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001516551 | SEC EDGAR / IRS |
| CUSIP | 83086J309 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001516551 | SEC EDGAR |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Net income (loss) (fiscal year ended 2025-12-31) | -$55,924,814 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-21 11:25 UTC | Report an error |
| Total assets (at 2025-12-31) | $28,313,633 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-21 11:25 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $20,024,175 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-21 11:25 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $5,882,498 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-21 11:25 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-21 11:25 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-21 11:25 UTC | Report an error |
| State of incorporation | NV | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-21 11:25 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-21 11:25 UTC | Report an error |
| Business address | 11250 EL CAMINO REAL, SUITE 100, SAN DIEGO, CA, 92130 | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-21 11:25 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-13 | SEC EDGAR company profile | as filed | 2026-11-21 11:25 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$43,062,529 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-21 11:25 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $6,312 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-21 11:25 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $273,646 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-21 11:25 UTC | Report an error |
| Form D total offering amount (D filed 2024-03-27) | $40,000,000 | 2024-03-27 | D | as filed | 2026-11-21 11:25 UTC | Report an error |
| Form D total amount sold (D filed 2024-03-27) | $40,000,000 | 2024-03-27 | D | as filed | 2026-11-21 11:25 UTC | Report an error |
| Form D industry group | Biotechnology | 2024-03-27 | D | as filed | 2026-11-21 11:25 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2024-03-27 | D | as filed | 2026-11-21 11:25 UTC | Report an error |
| Form D date of first sale | 2024-03-13 | 2024-03-27 | D | as filed | 2026-11-21 11:25 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-13 · accession 0001628280-26-073810
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | $69,126 | 3 months ended 2026-09-30 | 10-Q | 2026-11-13 | 0001628280-26-073810 | 2026-11-21 11:25 UTC | Report an error |
| Interest expense | $3,299 | 3 months ended 2026-09-30 | 10-Q | 2026-11-13 | 0001628280-26-073810 | 2026-11-21 11:25 UTC | Report an error |
| Cash and cash equivalents | $4,815,851 | at 2026-09-30 | 10-Q | 2026-11-13 | 0001628280-26-073810 | 2026-11-21 11:25 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-13 Filing 10-Q filed
- 2026-11-12 Filing DEFA14A filed
- 2026-11-12 Filing 8-K filed: Item 8.01 other event
- 2026-10-28 Filing PRER14A filed
- 2026-10-26 Filing PREM14A filed
- 2026-09-11 Filing DEFA14A filed
- 2026-09-11 Filing 8-K filed: Item 1.02 agreement terminated; Item 5.02 officer or director change; Item 8.01 other event
- 2026-08-24 Filing DEFA14A filed
- 2026-08-24 Filing 8-K filed: Item 1.01 material agreement; Item 3.02 unregistered equity sale; Item 9.01 exhibits
- 2026-08-20 Filing DEFA14A filed
- 2026-08-20 Filing 8-K/A filed: Item 3.03 rights of holders modified
- 2026-08-19 Filing DEFA14A filed
- 2026-08-19 Filing 8-K filed: Item 3.01 delisting notice
- 2026-08-14 Filing DEFA14A filed
- 2026-08-14 Filing 10-Q filed
- 2026-08-14 Filing 8-K filed: Item 1.01 material agreement; Item 3.02 unregistered equity sale; Item 3.03 rights of holders modified; Item 5.01 change in control; Item 5.02 officer or director change; Item 5.03 charter or bylaw amendment; Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2026-06-23 Filing 8-K filed: Item 8.01 other event
- 2026-05-29 Filing 8-K filed: Item 5.03 charter or bylaw amendment; Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-05-15 Filing 8-K filed: Item 3.01 delisting notice
- 2026-05-11 Filing 10-Q filed
- 2026-04-16 Filing ARS filed
- 2026-04-16 Filing DEFA14A filed
- 2026-04-16 Filing DEF 14A filed
- 2026-04-06 Filing PRE 14A filed
- 2026-04-06 Filing PREM14A filed (DEF 14A)
8-K item text, as filed (excerpts)
- 2026-11-12 8-K Item 8.01, Other Events
As previously disclosed in Part II, Item 1 of the Quarterly Report on Form 10-Q filed by Skye Bioscience, Inc. (the “Company”) with the Securities and Exchange Commission on August 14, 2026, a former employee of the Company filed a lawsuit, entitled Wendy Cunning vs Skye Bioscience, Inc., in the U.S. District Court for the Central District of California (the “District Court”) alleging violation of whistleblower protections under the Sarbanes-Oxley Act of 2002, and retaliation under California law against the Company relating to certain actions and events that occurred with the Company’s former management during the employee's employment term from March 2018 to July 2019. The complaint… the 8-K · retrieved 2026-11-21 11:25 UTC - 2026-09-11 8-K Item 1.02, Termination of a Material Definitive Agreement
On September 8, 2026, in connection with the resignation of John P. Sharp as Chief Financial Officer and principal financial and accounting officer of Skye Bioscience, Inc., a Nevada corporation (the “Company”), the Company provided written notice to Lohman & Associates, Inc. of its intent to terminate the Master Services Agreement, dated March 31, 2026, by and between the Company and Lohman & Associates, Inc. (the “Master Services Agreement”), effective September 8, 2026 (the “Effective Date”). The foregoing description of the Master Services Agreement is qualified in its entirety by reference to the full text of such agreement, which is filed as Exhibit 10.1 to the Company’s Current… the 8-K · retrieved 2026-11-21 11:25 UTC - 2026-09-11 8-K Item 8.01, Other Matters
On September 8, 2026, the Company received a letter from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s common stock had a closing bid price at or greater than $1.00 per share for the last 10 consecutive business days, from August 24 through September 4, 2026, and, as a result, the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market and the matter is now closed. Important Information and Where to Find It In connection with the proposed acquisition of Redx Pharma Limited (“Redx”) by Skye Bioscience, Inc.… the 8-K · retrieved 2026-11-21 11:25 UTC - 2026-08-24 8-K Item 1.01, Entry into a Material Definitive Agreement
As previously disclosed on the Current Report on Form 8-K filed by Skye Bioscience, Inc., a Nevada corporation (the “Company”), with the U.S. Securities and Exchange Commission (the “SEC”) on August 14, 2026, concurrently with the entry by the Company into (1) that certain Transaction Agreement (the “Transaction Agreement”) with Redx Pharma Limited, a private limited company incorporated in England and Wales with registered number 07368089, and (2) that certain Securities Purchase Agreement (the “PIPE SPA”) with the investors identified therein (the “PIPE Investors”), on August 14, 2026, the Company entered into a binding term sheet (the “Term Sheet”) with a fund affiliated with Redmile… the 8-K · retrieved 2026-11-21 11:25 UTC - 2026-08-24 8-K Item 3.02, Unregistered Sales of Equity Securities
To the extent required by this Item, the information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. The ELOC Shares, the ELOC Conversion Shares, the Warrant and the Warrant Shares will be issued without registration pursuant to the exemption provided by Section 4(a)(2) of the U.S. Securities Act of 1933, as amended. the 8-K · retrieved 2026-11-21 11:25 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1516551.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001516551. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.